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Abstract
Objective: The lysosomal storage disease alpha-mannosidosis is caused by the
deficiency of the lysosomal acid hydrolase alpha-mannosidase (LAMAN) lead-
ing to lysosomal accumulation of neutral mannose-linked oligosaccharides
throughout the body, including the brain. Clinical findings in alpha-mannosi-
dosis include skeletal malformations, intellectual disabilities and hearing impair-
ment. To date, no curative treatment is available. We previously developed a
beneficial enzyme replacement therapy (ERT) regimen for alpha-mannosidase
knockout mice, a valid mouse model for the human disease. However, humoral
immune responses against the injected recombinant human alpha-mannosidase
(rhLAMAN) precluded long-term studies and chronic treatment. Methods:
Here, we describe the generation of an immune-tolerant alpha-mannosidosis
mouse model that allowed chronic injection of rhLAMAN by transgenic expres-
sion of a catalytically inactive variant of human LAMAN in the knockout back-
ground. Results: Chronic ERT of rhLAMAN revealed pronounced effects on
primary substrate storage throughout the brain, normalization of lysosomal
enzyme activities and morphology as well as a decrease in microglia activation.
The positive effect of long-term ERT on neuronal lysosomal function was
reflected by an improvement of cognitive deficits and exploratory activity. in
vivo and in vitro uptake measurements indicate rapid clearance of rhLAMAN
from circulation and a broad uptake into different cell types of the nervous sys-
tem. Interpretation: Our data contribute to the understanding of neurological
disorders treatment by demonstrating that lysosomal enzymes such as rhLA-
MAN can penetrate into the brain and is able to ameliorate neuropathology.
Introduction
Alpha-mannosidosis is a devastating inherited autosomal
recessive lysosomal storage disease (LSD) caused by
deficiency of the lysosomal acid alpha-mannosidase
(LAMAN) encoded by MAN2B1.1,2 To date, 125 different
disease-causing mutations were identified affecting enzymatic
activity, stability and intracellular transport of LAMAN.3–6
Lysosomal deficiency of LAMAN leads to the accumulation
of free mannose-containing oligosaccharides of asparagine
(N)-linked glycans derived from proteolysis of glycoproteins
within the lysosomal compartment7 as well as impaired trim-
ming of N-linked oligosaccharides on native lysosomal
proteins.8 Cells with storage pathology are found throughout
the body, including the peripheral and central nervous system
(CNS). Alpha-mannosidosis presents with a wide spectrum
of symptoms typically, including recurrent infections,
impaired hearing, dysostosis multiplex, and progressive men-
tal retardation.9,10 To date, no curative therapy for
alpha-mannosidosis is in clinical practice. Bone marrow
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transplantation was efficient in alpha-mannosidosis cats11
but with variable outcome for patients.12
A promising therapeutic approach for an effective
treatment of alpha-mannosidosis is the application of
recombinant human LAMAN (rhLAMAN) into the
bloodstream, designated as enzyme replacement therapy
(ERT). This concept was based on findings on cross-
correction in cultured patient’s fibroblasts from Hurler
Syndrome with healthy cells.13 So far, several LSDs
including Morbus Gaucher (Type I), mucopolysacchari-
doses (I, II, VI), Morbus Fabry, and Morbus Pompe have
been shown to benefit from ERT.14 We have previously
demonstrated the value of high-dose short-term ERT on
clearance of primary brain substrate storage in alpha-
mannosidase-deficient (knockout) mice,15 a valid mouse
model for the human disease, using rhLAMAN of a
laboratory scale batch.16–18 However, immunological
responses to the injected enzyme associated with high
mortality precluded long-term ERT of this mouse strain.
To evaluate the chronic curative effect of enzyme applica-
tion, we have generated an immune-tolerant mouse
model and studied the effect of high-dose long-term ERT
on CNS pathology, using industrial produced rhLAMAN
which is used to treat alpha-mannosidosis patients in a
phase I-II clinical ERT trial.19 Strikingly, despite the low
number of patients, a significant improvement of motor
and to some extent also of cognitive function was
observed. Due to the limited accessibility of human brain
material, no correlation with a decline of primary sub-
strate storage and other neuropathological parameters
could be drawn.
We report a substantial clearance of primary stored
oligosaccharides in brain of immune-tolerant alpha-man-
nosidosis mice after long-term ERT accompanied by a
normalization of lysosomal enzyme activity, protein
expression and morphology. Furthermore, a deterioration
of secondary pathological alterations such as neuroinflam-
mation was prevented and an improvement of behavioral
anomalies achieved. Overall, our data suggest that chronic
ERT with rhLAMAN is a valuable tool to ameliorate the
observed CNS pathology in alpha-mannosidosis.
Material and Methods
Materials
A detailed description of the material, reagents and anti-
bodies used can be found under Data S1.
Experimental animals
Alpha-mannosidase knockout mice were described previ-
ously15 and are here referred to alpha-mannosidosis mice
(-/-). A detailed description of the generation of the trans-
gene can be found under Data S1. Animals were main-
tained in a conventional animal facility. All procedures
performed in this study involving animals were in accor-
dance with the ethical standards set by the National Ani-
mal Care Committee of Germany.
Purification of rhLAMAN and intravenous
injection
Purification of Chinese hamster ovary-derived rhLAMAN
from cell culture supernatants was described previ-
ously.16,19 RhLAMAN (64 U/mL; 2 mg/mL) was injected
into the tail vein at doses of 25, 125, 500, or 1000 U/kg
per body weight (bw) (corresponding to 0.9, 4.4, 15.6,
and 31.2 mg/kg per bw, respectively). Mock-injected mice
received the same volume of phosphate-buffered saline
(PBS). Prior to dissecting organs for biochemical and
histological analysis, if not stated otherwise, mice were
perfused at least 24 h after the last enzyme injection with
0.1 mol/L phosphate buffer in order to clear the circula-
tion from residual enzyme. All animal experiments were
approved by local authorities (Tierversuchsantragsnum-
mer: V 312-72241.121-3 (32-3/10)).
Behavioral experiments
Prior to behavioral experiments, mice received biweekly
injections during 12 weeks of either 500 U/kg rhLAMAN
(ERT-treated -/- tg+ mice) or saline solution (mock-trea-
ted -/- tg+ and +/- tg+ control mice) (all n = 13-14).
Behavioral experiments were executed during the
following 2 weeks while treatment continued. Mice were
3-4 months at the start of treatment. Injections were
given after daily testing to avoid interference with behav-
ioral experiments. The behavioral test battery included an
open field (exploration and emotion), water maze (learn-
ing and memory), and treadmill (motor performance). A
detailed description of the behavioral analyses can be
found under Data S1.
Immunohistology and immunofluorescence
Immunohistological and immunofluorescent staining were
performed on formalin-fixed free-floating tissue sections
or cultured cells according to standard laboratory proto-
cols. A detailed description can be found in Data S1.
Preparation of primary mixed neuronal and
glial cultures
Primary mixed neurons and glial cells were prepared as
described previously20 from the cortices of gestational day
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15 embryos. Cells were fixed in 4 % paraformaldehyde
diluted in PBS after 14 days in vitro.
Enzyme-linked immunosorbent assay
(ELISA) for detection of LAMAN-specific IgG
in plasma
A detailed description can be found under Data S1.
Preparation of tissue lysates, SDS-PAGE,
immunoblotting, and enzyme activity
measurements
Tissues were homogenized in PBS-containing Triton X-
100 and cleared by centrifugation at 16.000 9 g for
20 min at 4°C. Lysates were separated on 12.5 % sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) gels, blotted on nitrocellulose membrane and
detected with appropriate antibodies according to stan-
dard procedures, using Horse radish peroxidase (HRP)-
coupled secondary antibodies and chemiluminescence.
The activity of standard lysosomal enzymes was deter-
mined colorimetrically in tissue homogenates under acidic
conditions as described.16
Oligosaccharide extraction, TLC and HPLC
Oligosaccharide extraction and thin layer chromatography
(TLC) analysis of neutral oligosaccharides was performed
essentially as described previously.16 A detailed descrip-
tion of oligosaccharide extraction, TLC and high-perfor-
mance liquid chromatography (HPLC) analyses can be
found under Data S1.
Statistical analyses
For statistical analysis, all samples were normalized to
controls in each experiment, and quantification was rep-
resented as the mean  SEM. Data were plotted with
GraphPad Prism. Statistical significance, using unpaired
Student’s t-test was calculated with GraphPad Prism (Ver-
sion 5.04) (GraphPad Software, La Jolla CA, USA) and
statistical significance was set at: ns, nonsignificant,
P > 0.05, *P < 0.05, **P < 0.01, and ***P < 0.001.
Results
Generation of immune-tolerant alpha-
mannosidosis mice that permit chronic
injections of rhLAMAN
Repeated injections every other week of low and high
doses (25 and 500 U/kg, corresponding to 0.9 and
15.6 mg/kg per bw) rhLAMAN in alpha-mannosidosis
mice (-/-) led to increased mortality (Fig. 1A) during
16 weeks of treatment due to a humoral immune
response revealed by an increase in LAMAN-specific IgG
in the plasma of ERT-treated mice (Fig. S1A). Treatment
with 500 U/kg caused an earlier onset of the immune
response compared to the low dose, whereas the survival
rate was dosage-independent and all mice died during
treatment. To enable chronic ERT, we developed
immune-tolerant alpha-mannosidosis mice by transgenic
expression of an active site mutant of human LAMAN
under the control of the b-actin promotor in the alpha-
mannosidase knockout background. The insertion of a
clinical mutation (c.215: A>T) within the human LAMAN
cDNA leads to an exchange of a histidine to leucine at
position 72 (H72L) in the active site resulting in an
inactive form of the enzyme, which still localizes to lyso-
somes4,5 (Fig. S1B–D). Finally, homozygote alpha-man-
nosidase knockout mice that were heterozygote for the
LAMAN-Mut-H72L transgene (-/- +tg) were obtained.
Transgene expression was validated by immunoblot analy-
sis, which revealed a transgenic-driven expression of
LAMAN in all tissues investigated (brain, spleen, liver,
heart, kidney, and lung) as depicted for brain and spleen
in Figure 1B. Brain sections that were immunologically
stained for LAMAN revealed broad expression of the
transgene throughout the CNS, including cerebellum, hip-
pocampus, and cortex (Fig. 1C). The specificity of the
antibody was verified in nontransgenic knockout mice
(Fig. S1E). Alpha-mannosidase activity was detectable in
the wild-type (+/+) but not in lysates derived from the
CNS (brain) and visceral tissues (spleen) of both knock-
out strains (-/- +tg and -/-) (Fig. 1D), indicating expres-
sion of transgenic inactive LAMAN. Finally, we
determined LAMAN-specific IgG in the plasma of trans-
genic and nontransgenic knockout mice which received
seven weekly injections of 500 U/kg (Fig. 1E). Nontrans-
genic mice developed high antibody levels immediately
after the first injection and died upon further treatment,
whereas transgenic knockout animals developed only neg-
ligible plasma levels of LAMAN-specific IgG and tolerated
the injected enzyme. Overall, our data demonstrate
successful induction of immune-tolerance to recombinant
LAMAN due to transgenic expression of an inactive vari-
ant of the enzyme.
Neuropathological characterization of
immune-tolerant alpha-mannosidosis mice
We then assessed whether transgenic knockout mice reflect
the human pathology comparable to the conventional
alpha-mannosidase knockout mice15 and are suitable to
study the impact of chronic ERT on neuropathology.
ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 989
M. Damme et al. ERT in alpha-Mannosidosis Mice
Therefore, transgenic and nontransgenic knockout mice as
well as wild-type mice were analyzed for storage and sec-
ondary pathological changes.8,16 TLC analyses revealed
comparable accumulation of oligosaccharides linked to 2-9
mannose residues (Man2-Man9) between both genotypes
in brain (Fig. 2A) and spleen (Fig. S2A) which was con-
firmed by HPLC-based quantification of Man2-Man4
(Fig. 2B, Fig. S2B). In brain, both genotypes displayed a
similar increase in the specific activity of the lysosomal
enzymes b-glucuronidase (GUS), b-hexosaminidase and
b-galactosidase (Fig. 2C). The presence of storage vacuoles
is a prominent feature of alpha-mannosidosis in mice15,16
and men.21,22 Ultrastructural analyses revealed comparable
presence of storage vacuoles in neurons of the ganglion
trigeminale, hippocampus, and Purkinje cells of the cere-
bellum (Fig. 2D). Visceral tissues such as the pancreas also
displayed a comparable storage phenotype between both
genotypes (Fig. S2C). These storage vacuoles are strongly
positive for the Lysosome-associated membrane glycopro-
tein 1 (LAMP-1).17 Morphological examination of brain
sections immunologically stained for LAMP-1 displayed a
similar increase in vesicular labeling of LAMP-1 within
neurons of the hippocampus, cerebellum, and cortex
(Fig. 2E) of both genotypes. Finally, we compared neu-
ropathological alterations such as microglia activation
which appear secondary to primary substrate storage.17 A
similar degree of microglia activation as indicated by
increased labeling with CD68 throughout the cortex was
evident (Fig. 2F). We conclude that immune-tolerant
alpha-mannosidosis mice are a valuable disease model to
study the impact of preclinical long-term ERT on neu-
ropathology, using recombinant human enzyme.
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Figure 1. Transgenic alpha-mannosidase knockout mice express inactive human LAMAN and are immune-tolerant. (A) Repeated injections every
other week of recombinant human LAMAN with doses of 25 and 500 U/kg into the tail vein of nontransgenic alpha-mannosidase knockout mice
(-/-) leads to premature death during 16 weeks of treatment whereas mock-injected mice (-/- PBS) were not affected. (B) Immunoblot analyses of
tissue lysates revealed transgene driven expression of inactive human LAMAN in brain and spleen of transgenic 14 knockout mice (-/- +tg) but not
in nontransgenic wild-type (+/+) and knockout (-/-) tissue. LAMAN-specific bands detected at about 130, 70 and 14 kDa correspond to the
precursor (p) and lysosomal processed forms (m) of LAMAN. (C) Transgenic expression of LAMAN throughout the central nervous system
including cerebellum, hippocampus and cortex as determined by 3,3’-Diaminobenzidine (DAB)-immunohistochemistry, using a LAMAN-specific
antibody (Scale bars = 500 lm). (D) alpha-mannosidase activity of brain and spleen homogenates indicates lack of enzymatic activity in both
knockout mouse strains. (E) The antibody (LAMAN-specific IgG) response in plasma of transgenic knockout mice compared to nontransgenic
animals is reduced as determined by an ELISA after seven weekly injections of 500 U/kg (*P < 0.05). LAMAN, lysosomal acid alpha-mannosidase;
PBS, phosphate-buffered saline; ELISA, enzyme-linked immunosorbent assay.
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Figure 2. Immune-tolerant transgenic alpha-mannosidosis mice are phenotypically indistinguishable from nontransgenic animals. (A) Separation of
neutral oligosaccharides extracted from brains of 3-4 months old wild-type (+/+), nontransgenic (-/-) and transgenic (-/- +tg) mice by TLC shows
comparable amounts of all glycan species (Man2–Man9). (B) Quantitative analysis of oligosaccharides by high pressure liquid chromatography
indicate equal levels of the major glycan species Man2 and Man3 (n = 3-4, per genotype). (C) a-glucuronidase, b-hexosaminidase and a-
galactosidase show a similar increase in their specific activity in brain extracts of nontransgenic and transgenic knockout mice compared to wild-
type animals (n = 3, per genotype). (D) Light microscopy of Toluidine-stained semithin sections from the ganglion (G.) trigeminale, hippocampus
and cerebellum reveals similar amount of storage vacuoles in both knockout strains. Scale bar: 50 lm, insets show zoomed images of the outlined
area; stars (*) highlight vacuolated storage cells. (E) Immunofluorescence labeling of LAMP-1 revealed a similar increase in LAMP-1 levels in -/- and
-/- tg+ mice compared to +/+ animals in the hippocampus, cerebellum and the cerebral cortex (Scale bar: 50 lm). (F) Reactive microglia (green) are
present to a similar degree in the molecular layer of the cerebellum of -/- and -/- tg+ mice (4’,6-Diamidin-2-phenylindol (DAPI), blue; Scale bar:
50 lm) (*P < 0.05, **P < 0.01, ***P < 0.001). TLC, thin layer chromatography; LAMP-1, Lysosome-associated membrane glycoprotein 1.
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Effect of ERT on primary substrate storage
in immune-tolerant alpha-mannosidosis
mice
We next evaluated the efficacy of a 12-week ERT protocol
in reducing primary substrate storage of the CNS and
peripheral tissues. In this experimental set-up either non-
transgenic wild-type or nontransgenic heterozygote ani-
mals served as controls.15 In previous studies, we
demonstrated that four biweekly injections of 500 U/kg
rhLAMAN were necessary to significantly reduce CNS
storage when applied short term.16 In order to investigate
the chronic impact of this ERT regimen and whether
chronic treatment can compensate for a lower dose, 4-
6 weeks old mice with an established blood-brain bar-
rier23,24 were biweekly injected with 125 and 500 U/kg
rhLAMAN (corresponding to 4.4 and 15.6 mg/kg per
bw), respectively. ERT was completed at an age of 16-
18 weeks, a time point where alpha-mannosidosis mice
display a prominent storage phenotype.16,17 Of note, for
this and the following experiments prior to harvesting
brain and other organs, mice were perfused with phos-
phate buffer to avoid contamination with plasma-derived
rhLAMAN. Enzyme injections led to a dose-dependent
increase of alpha-mannosidase activity in brain reaching
72 % of the endogenous wild-type level at 500 U/kg
(Fig. 3A). Accordingly, TLC analysis of brain oligosaccha-
rides revealed a dose-dependent decrease of all glycan spe-
cies in mice treated with 125 and 500 U/kg (Fig. 3B).
Similar results were obtained by quantitative HPLC analy-
sis which revealed a 37 % (125 U/kg) and 68 % (500 U/
kg) decrease of the most abundant oligosaccharide species
Man2 in rhLAMAN-treated mice when compared to
control mice (Fig. 3C). In wild-type brains, mannosy-
lated-glycans were below detection levels. Histological
examination of brain sections revealed less storage
vacuoles in hippocampal neurons of 125 U/kg treated
animals in comparison to control mice, whereas use
of 500 U/kg led to an almost complete disappearance
of storage vacuoles (Fig. 3D). The normalization of
lysosomal function in response to the applied ERT regi-
men was verified by a significant decline in GUS and
b-hexosaminidase activity (Fig. 3E). Furthermore, a
decrease in LAMP-1 immunoreactivity in brain sections
of ERT-treated mice was also evident (Fig. 3F). Among
all brain regions investigated, hippocampal and cortical
neurons responded best to ERT as indicated by a gradu-
ally decrease in LAMP-1 immunoreactivity after treatment
with either 125 or 500 U/kg, respectively. The cerebellum
apparently benefited least from the applied ERT regimen
(Fig. 3F, lower panel). In contrast to the CNS, peripheral
tissues such as kidney (Fig. S3A and B) and spleen
(Fig. S3C and D) showed an efficient clearance of
oligosaccharides as determined by TLC and HPLC analy-
ses at either dose. This was also reflected by a complete
absence of storage vacuoles within all histologically exam-
ined peripheral tissues, including pancreas, kidney, and
ganglion trigeminale (Fig. S3E). Our data suggest an effi-
cient and beneficial uptake of chronically injected rhLA-
MAN into cells of visceral tissues and the CNS with a
clear dose- and regional-dependent effect in the brain.
Effect of ERT on secondary
neuropathological alterations in immune-
tolerant alpha-mannosidosis mice
After evaluating the long-term effect of ERT on neuronal
oligosaccharide accumulation and lysosomal morphology
we determined the effect of ERT on secondary
neuropathological alterations in elder mice in which neu-
ropathology, including microgliosis is apparent. The ERT
regimen was started at 4 months of age by injecting
(biweekly) 500 U/kg rhLAMAN (corresponding to
15.6 mg/kg per bw) during 14 weeks. The efficacy of ERT
was verified by a decline in primary oligosaccharide stor-
age and LAMP-1 levels as well as a normalization of lyso-
somal enzyme activities (Fig. S4). Chronic treatment of
immune-tolerant mice significantly attenuated microglia
activation in the hippocampus, cerebral cortex, and thala-
mus as determined by immunofluorescence staining for
CD68. However, no positive effect of ERT treatment was
observed in the cerebellum, where phagocytic microglia
(Fig. 4A) and reactive Bergmann glia persisted even after
long-term ERT (Fig. 4B).
Figure 3. Long-term high-dose ERT efficiently reduces oligosaccharide storage within brain. (A) Alpha-mannosidase activity increases dose-
dependently in brain homogenates of transgenic (-/- +tg) mice after biweekly injections of 125 or 500 U/kg over 12 weeks of treatment. (B) TLC
analysis of oligosaccharide brain extracts of wild-type (+/+) and both knockout strains shows decreased levels of all major oligosaccharide species
in -/- +tg mice after ERT with both indicated doses. (C) HPLC-based quantification reveals a significant dose-dependent decrease of Man2 and
Man3 in treated -/- tg+ mice when compared to mock treated animals. (D) Toluidine blue-stained semithin sections display less storage vacuoles in
high dose (500 U/kg) treated -/- +tg mice when compared to non- and 125 U/kg treated mice. (E) ERT leads to a significant dose-dependent
decrease of lysosomal enzyme activities such as b-hexosaminidase and a-galactosidase and (F) a normalization of LAMP-1 immunoreactivity in
cerebral cortex (upper panel) and hippocampus (middle panel) but not in Purkinje cells of the cerebellum (*P < 0.05, **P < 0.01, ***P < 0.001).
ERT, enzyme replacement therapy; TLC, thin layer chromatography; HPLC, high-performance liquid chromatography; LAMP-1, Lysosome-
associated membrane glycoprotein 1.
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Effect of ERT on behavioral anomalies
observed in immune-tolerant alpha-
mannosidosis mice
We evaluated the functional benefit in the same cohort of
long-term ERT-treated mice described above, using a
behavioral test battery including open field (exploration
and emotion), water maze (learning and memory), and
treadmill (motor performance). Exploratory locomotion
was video-tracked during 10 min in a brightly illuminated
open field arena. Different zones were identified in the
analysis arena (corners, center) as well as time intervals
selected to evaluate spatial and temporal components of
exploration. Spatial analysis of the tracks revealed signifi-
cant differences between the groups for time in the center
(Fig. 5A; P < 0.05) and % path length in the center
(Fig. 5B; P < 0.05), and a trend for the number of center
entries (P = 0.06; not shown). In general, -/- tg+ mice dis-
played reduced exploration of the center of the arena show-
ing no improvement after ERT. However, temporal
analysis of exploration showed different relationships
between the experimental groups. Analysis of cumulative
path length (Fig. 5C) indicated an early onset decline in
mock-treated -/- tg+ mice, while enzyme-treated animals
progressively fell behind control mice. Indeed, when divid-
ing the 10 min exploration time into three equal intervals
(3 min 20 sec; Fig. 5D), there was a significant
Group 9 Interval interaction on total path length
(P < 0.05). Control mice (P < 0.05) showed increased
exploratory activity in the first interval in comparison with
mock-treated -/- tg+ mice. Of note, mice receiving enzyme
treatment were indistinguishable from control mice. More-
over, control mice and enzyme-treated -/- tg+ mice showed
similar distribution of exploratory activity, indicated by an
initial exploratory peak and significant decline of activity
over time. There was a significant difference between inter-
val I and III for control mice (P < 0.01) and enzyme-trea-
ted -/- tg+ mice (P < 0.001). On the contrary, mock-
treated -/- tg+ mice showed no changes in exploration over
time. In conclusion, ERT did not improve central explora-
tory measures in -/- tg+ mice but normalized the temporal
aspect of exploration.
During the acquisition phase of the water maze experi-
ment, mice were trained for 5 days (trial blocks I-V) to
learn the location of a hidden escape platform (Fig. 5E).
Mock-treated -/- tg+ mice were slower to locate the plat-
form during the first trial block than control and ERT-
treated -/- tg+ mice (P < 0.05 and <0.01), but eventually
reached a similar level of performance. After 2 days of
rest, a 100 sec probe trial is performed during which the
platform is removed. Preference for the target quadrant is
analyzed as an index of long-term reference memory.
Control mice showed a preference for the target quadrant,
spending significantly more time there in comparison
with the three other quadrants (Fig. 5F). ERT-treated -/-
tg+ mice spent most time in the target quadrant, but dis-
played less spatial accuracy (no significant difference vs.
the adjacent quadrants). Mock-treated -/- tg+ mice pre-
ferred the target quadrant, but also quadrant Adj1 over
Adj2 and the opposite quadrant. Individual analysis of
spatial preference (Fig. 5G) revealed that 55 % of the
mock-treated -/- tg+ mice (P < 0.05) and 50 % of the
ERT-treated -/- tg+ mice (P < 0.05) showed an erroneous
preference for another quadrant, while this was only the
case for 6 % of control mice (Group effect P < 0.05). In
conclusion, The ERT treatment did not improve the
impaired long-term reference memory, but led to a cor-
rection of the learning deficit in the first acquisition trial
block, which more likely reflects improvements in short-
term working memory.
During the treadmill experiment (Fig. 5H), motor per-
formance is analyzed by evaluating the ability of mice to
keep pace with a motorized treadmill belt. Mock-treated
-/- tg+ mice showed significantly less error latencies in
comparison with the control group (P < 0.05), while
enzyme treatment revealed a trend of -/- tg+ mice for
increased error latencies. This confirms previous findings
of improved motor performance after short-term ERT.
Uptake studies of rhLAMAN in brain and
primary cultured neuronal and glial cells
We next investigated the clearance of rhLAMAN from cir-
culation as well as the accessibility of the CNS to the
injected enzyme by injecting one-single high enzyme dose
(1000 U/kg, corresponding to 31.2 mg/kg per bw) to
obtain measurable enzyme activity in brain.16 At different
time points, after administration (5 min, 1 h, 5 h, and
16 h), blood was taken and LAMAN activity determined.
We included both wild-type and nontransgenic knockout
mice in our analysis to exclude genotype-specific effects
such as impairment of the blood-brain barrier or the
presence of high levels of mannose-rich oligosaccharides
in the serum of alpha-mannosidosis mice that might
influence enzyme uptake by competing with the recombi-
nant glycoprotein via carbohydrate-specific receptors. As
shown in Figure 6A, in both genotypes, the injected
enzyme was cleared from circulation rapidly and after
16 h only about a tenth of the initial enzyme activity in
plasma was detectable. LAMAN activity measurements
16 h after injection indicate a similar uptake of enzyme
into the brain of wild-type and knockout mice. Further-
more, a single injection of 1000 U/kg rhLAMAN is suffi-
cient to fully restore endogenous levels of LAMAN
activity in brain lacking alpha-mannosidase activity
(Fig. 6B).
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Our morphological analyses suggest a differential
response of various brain regions to high-dose ERT. To
determine whether a different accessibility of rhLAMAN
to various brain regions accounts for this effect, we have
used the same injection protocol as described above and
measured LAMAN activity within different brain regions,
including hippocampus, cortex, cerebellum, medulla
oblongata, pons and midbrain (Fig. 6C). In all brain
regions investigated, the applied ERT regimen was
sufficient to reach endogenous LAMAN activity with no
significant differences between LAMAN activities in
various brain regions.
To evaluate the ability of rhLAMAN to target different
cell types of the CNS, we have performed in vitro uptake
experiments using mixed primary neuronal and glial pri-
mary cultures followed by immunofluorescence staining,
using an rhLAMAN-specific antibody. Co-staining with dif-
ferent cellular markers such as the Microtubule-associated
protein type 2 (MAP-2), the Glial fibrillary acidic protein
(GFAP) and macrosialin/CD68 were used to identify neu-
rons, astroglia, and microglia cells, respectively (Fig. 6D).
RhLAMAN was preferentially taken up by CD68-labeled
microglia cells whereas only a few neurons and astrocytes
stained positive for the recombinant enzyme. Lysosomal
localization of rhLAMAN was verified by co-staining with
LAMP-2. Enhanced LAMAN activity was observed in the
same mixed cultures after treatment with the enzyme
(Fig. 6E). Similarly, uptake of the enzyme was verified via
immunoblotting (Fig. 6F). Overall, our data indicate rapid
clearance of rhLAMAN from circulation and a preferential
uptake into microglial cells in vitro. Importantly, a single
injection of a high dose of rhLAMAN is sufficient to restore
endogenous alpha-mannosidase activity in the brain.
Discussion
Lysosomal storage disorders (LSDs) are devastating,
mostly neurodegenerative diseases with limited therapeu-
tic options. However, despite the long-standing dogma
that lysosomal enzymes cannot cross the blood-brain
barrier, within recent years, preclinical research has
demonstrated the power of specific ERT regimens to even
ameliorate CNS pathology. In this paper, we describe the
generation of a novel immune-tolerant mouse model
for alpha-mannosidosis showing histopathological,
biochemical and behavioral characteristics comparable to
the conventional alpha-mannosidase knockout mice.15 A
similar approach, describing the successful induction of
immune tolerance by transgenic expression of an active
site mutant in various LSD mouse models has been used
by others.25–27 Immune-tolerant mice were instrumental
in investigating the effect of long-term ERT in other LSDs
such as Pompe disease,28 mucopolysaccharidosis-type VII
(MPSVII),26 and metachromatic leukodystrophy.25 Beside
its value for systemic high-dose ERT, our immune-toler-
ant mouse model is also useful in order to test other
therapeutic approaches such as intrathecal delivery of
(un)modified rh LAMAN preparations or gene therapy.
In contrast to visceral tissues, the long-term benefit of
ERT on neuronal function in alpha-mannosidosis mice,
represented by a substantial decline in primary substrate
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storage and a normalization of lysosomal function as well
as an improvement of behavioral deficits, was only appar-
ent after high-dose enzyme injections (500 U/kg). This is
in agreement with our previous studies16 showing that
high enzyme doses are necessary to get sufficient amounts
of enzyme into the CNS leading to a substantial reduction
of brain storage when applied short term, suggesting a
dose-dependent uptake of the recombinant enzyme into
the brain. Our studies are in agreement with other pre-
clinical ERT studies in LSD animal models showing
mostly beneficial effects of high-dose injections of recom-
binant enzymes on primary lysosomal storage reduction
and improvement of secondary pathological alterations
such as neuroinflammation and behavioral deficits.29–33
Of note, in our preclinical study, the beneficial effect of
ERT was most prominent for the 500 U/kg dosage but
still significant at 125 U/kg for most of the parameters
analyzed, suggesting that chronic treatment can at least to
some extent compensate for lower enzyme activity. The
precise mechanism as to how the systemically applied
recombinant enzymes can cross the blood-brain barrier
remains to be established. According to Sly and coworkers
using recombinant GUS in preclinical ERT studies with
MPSVII mice,24,34 mannose-6 phosphate receptors
(MPRs) that are responsible for intracellular lysosomal
targeting of most lysosomes enzymes and their cellular
uptake35,36 cannot account for the uptake of recombinant
lysosomal enzymes into adult brain due to their restricted
expression in brain endothelial cells within the perinatal
period (2 weeks after birth). In adult animals which lack
expression of endothelial MPRs, administration of recom-
binant enzymes bearing mannose 6-phosphate (M6P)
residues might even diminish their uptake into brain as
demonstrated for GUS.24,30,34 Of note, recombinant rhLA-
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MAN which, in comparison with other lysosomal
enzymes, is highly efficient in clearance of brain primary
substrate storage is only marginally phosphorylated, sug-
gesting primarily M6P-independent uptake.16 Low phos-
phorylation content was shown to correlate with an
increased half-life of recombinant enzymes such as
GUS34,37 and alpha-mannosidase.38 A prolonged circula-
tion was suggested to enable the transfer of higher
amounts of lysosomal enzymes into the brain. Therefore,
deglycosylation or chemical modification was used to
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increase the circulatory half-life of lysosomal enzymes
such as Tripeptidyl peptidase type 1 (TTP1)39 and
GUS.30,40 However, in contrast to GUS, glycan modifica-
tion of TTP1 did not improve its targeting to brain. Fur-
ther uptake studies, using different preparations of
recombinant enzymes that are commercially available are
therefore necessary to elucidate whether modification of
the glycan structure and/or a low phosphorylation con-
tent in general, or only in the case of specific enzymes
can improve brain uptake. Furthermore, it should be
investigated if an earlier onset of treatment might result
in improved efficacy of ERT, as described for other pre-
clinical ERT in murine LSD models.41–44 Impairment of
the blood–brain barrier integrity in LSDs represents
another pathway of how an enzyme can reach the brain.14
However, in our preclinical studies, the uptake of rhLA-
MAN into the brain of wild-type and alpha-mannosidosis
mice was comparable, suggesting that the specific nature
of the enzyme rather than permeable tight-junctions
account for the observed brain uptake. The application of
high enzyme doses is not a guarantee for sufficient brain
uptake since several other ERT approaches did not show
beneficial effects on the CNS even upon use of high
doses.45–47
Most ERT studies showing beneficial effects on the
CNS reached only the sub-endogenous enzyme activity
level.32,46,48 In contrast, with the applied ERT regimen, we
fully restored endogenous LAMAN activity levels in all
CNS regions investigated. Of note, in comparison with
other lysosomal enzymes such as b-hexosaminidase and
GUS, the endogenous activity of LAMAN in brain is
extremely low and 20-fold less as compared to the liver.
Therefore, it is tempting to speculate that due to the low
endogenous activity of LAMAN in the CNS, only minor
fractions are needed to restore endogenous activities.
It should be highlighted that by including a factor of
10 that relates surface area to body weight between mouse
and men,49 the applied 500 U/kg dosage used in our pre-
clinical studies exactly matches the dose of 50 U/g applied
weekly to alpha-mannosidosis patients in a first phase I–
II clinical trial.19 Remarkably, despite the low number of
patients (n = 10), chronic ERT of 12 months led to a sig-
nificant decline of oligosaccharide levels in urine, serum,
and cerebrospinal fluid (CSF) as well as decreased levels
of the CSF-biomarkers Tau-protein and GFAP. Moreover,
a significant improvement of motor abilities and most
notably of cognitive functions was achieved, indicating
that our findings in the mouse model can be well
assigned to the clinical studies, at least for patients with
enzymatically inactive LAMAN variants. Patients lacking
expression of LAMAN1,3,6 may develop antibodies against
the recombinant enzyme affecting ERT efficacy. However,
in this first clinical study for alpha-mannosidosis the
frequency of infusion-related reactions as well as the
production of antibodies against the recombinant enzyme
was low19 in comparison with other ERT studies.50–54
Furthermore, these rhLAMAN-specific antibodies were
shown not to be neutralizing, suggesting only mild
immunological complications with regard to future ERT.
Our results implicate that a further increase in enzyme
dosing could be beneficial to the treatment of the disease
and that alpha-mannosidosis might be the first LSD for
which systemic ERT leads to significantly improved CNS
pathology.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Development of rhLAMAN-specific IgG in
alpha-mannosidase knockout mice and generation of
immune-tolerant alpha-mannosidosis mice. (A) Conven-
tional nontransgenic alpha-mannosidase knockout mice
(-/-) develop significant antibody responses after the sec-
ond injection of recombinant rhLAMAN as determined
by ELISA measuring LAMAN-specific IgG in plasma of
both low (25 U/kg) and high (500 U/kg) dose-treated
animals. (B) Schematic drawing of the pTVC vector con-
taining the mutated cDNA of human LAMAN carrying
the clinical H72L mutation under the control of the beta-
actin promotor. The SalI/NotI-excised expression cassette
of pTVC-LAMAN(MutH72L was injected into the pronu-
cleus of fertilized oocytes. (C) Genotyping strategy with
exon-specific primers flanking the inserted H72L muta-
tion (hLAMAN-H72L-F: 50-CACACACTTGATGACGT
CGGC-30 and hLAMAN-670R: 50-GATAATCAAGGCGCC
CAAAGAAG-30) identified three transgene-positive foun-
der lines (lines 4, 8 and 11). (D) Breeding scheme for the
generation of immune-tolerant transgenic knockout mice
(-/- +tg): transgene positive founder mice (Founder line
#4) were crossed with alpha-mannosidase knockout mice
(-/-) in the F0 generation. Transgene positive LAMAN
heterozygote animals were further crossed in the F1 gen-
eration with homozygous alpha-mannosidase knockout
mice (-/-) in order to obtain transgene-positive transgenic
knockout mice (-/- +tg) in the homozygote LAMAN
background in the F2 generation. (E) Antibody specificity
for the rhLAMAN staining shown in Figure 1 was proved
by absence of signals in DAB-stained brain sections of
nontransgenic alpha-mannosidase knockout mice (-/-)
1000 ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
ERT in alpha-Mannosidosis Mice M. Damme et al.
using a rhLAMAN-specific antibody. The images pre-
sented in Figure 1C and E were acquired under the same
experimental and microscopical settings.”
Figure S2. Immune-tolerant alpha-mannosidase knockout
mice are phenotypically indistinguishable from nontrans-
genic animals. (A) Separation of neutral oligosaccharides
extracted from spleens of 3–4 months old wild-type
(+/+), nontransgenic (-/-) and transgenic (-/- +tg) mice
by thin layer chromatography (TLC) shows comparable
amounts of all glycan species (Man2–Man9). (B) Quanti-
tative analysis of oligosaccharides by high-performance
liquid chromatography (HPLC) indicate equal levels of
the major glycan species Man2 and Man3 (n = 3–4, per
genotype). Light microscopy of Toluidine-stained semi-
thin sections from the pancreas reveals similar amounts
of storage vacuoles in both knockout strains (Scale bar:
50 lm).
Figure S3. Long-term high-dose ERT efficiently reduces
oligosaccharide storage within peripheral tissues. (A) TLC
analysis and (B) HPLC of oligosaccharides extracted from
kidney of wild-type (+/+) and both knockout strains
shows complete clearance of all major oligosaccharide
species in -/- +tg mice after ERT with both indicated
doses. Similar results were obtained for the spleen as
determined by both (C) TLC and (D) HPLC analyses. (E)
Light microscopy of Toluidine-stained ultrathin sections
from the pancreas, the kidney and trigeminal ganglion of
untreated and 125 U/kg treated animals shows complete
disappearance of vacuoles in all tissues after ERT.
Figure S4. Long-term high-dose ERT efficiently reduces
oligosaccharide storage in the brain of mice with estab-
lished neuropathology. (A) The specific activity of a-glu-
curonidase and b-hexosaminidase show a normalization
to control (+/-) levels after rhLAMAN treatment with
500 U/kg (n = 4–6, per genotype). (B) TLC analysis of
oligosaccharide brain extracts (upper panel) of both
knockout strains shows decreased levels of all major
oligosaccharide species in -/- +tg mice after ERT with
500 U/kg. Quantitative clearance of oligosaccharides is
also observed in the spleen (lower panel). (C) HPLC-
based quantification revealed a clear decrease of Man2–
Man4 oligosaccharides in treated -/- tg+ mice when com-
pared to untreated -/- +tg mice animals in the brain (up-
per panel) and a nearly complete clearance in the spleen
(lower panel). (D) Immunofluorescence labeling of
LAMP-1 revealed a normalization of LAMP-1 levels in -/-
and -/- tg+ mice compared to control mice (+/) in the
hippocampus, cerebellum, and the cerebral cortex (Scale
bar: 50 lm).
Data S1. Supplemental methods.
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